Other VEGF targeted therapies tested in the setting of pancreatic cancer include sorafenib, axitinib, and sunitinib but limited activity in phase II trials ended further investigations into these agents [76-78]. This evidence concerns the gene VEGFA and familial pancreatic carcinoma.